Would you like to decrease your dependency on glasses or contact lenses? This is now an option with the use of premium lifestyle lens implants. Individuals suffering from cataracts previously had only a monofocal lens implant option after surgery. NEW multifocal IOL technology provides multiple ranges of vision: near, intermediate and far, giving you the opportunity to reduce or even eliminate your dependency on glasses!
Did you know there is now advanced testing available for diagnosing macular degeneration? Macular Risk® is a DNA test that identifies genetic markers associated with Macular Degeneration. By analyzing these genetic markers along with smoking history, we can identify who needs more frequent eye examinations and who may benefit from eye vitamins.
NEW TECHNIQUES IN TREATING MACULAR DEGENERATION
Are you seeking clear vision without the hassles of glasses or contact lenses? There are many vision correction options available at Kaufman Eye Institute. Take our Vision Correction Self Test to learn what options are best for you!
TAKE THE VISION CORRECTION SELF TEST
The physicians and staff at the Kaufman Eye Institute take great pride in helping less fortunate countries receive the eye care that is much needed. Click here to learn about our most recent medical mission.
8/24/2011:
Best Eye Surgeon in the South Shore area.
Kaufman Eye Institute is gratified at being selected as the Best Eye Surgeon in the South Shore area. We have always strived to provide the absolute highest quality eye care for our patients. It is major accomplishment to know how patients feel about our practice and that they have taken the time to respond.
5/20/2011:
CATT first year results are in!
The Comparison of AMD Treatments Trial (CATT) is a head to head study of Avastin (bevacizumab) vs Lucentis (ranibizumab) funded by the National Eye Institute. The highly anticipated first year results of the two year study have been released.
Take home points:
Philip J. Rosenfed, MD, Ph.D., the physician who pioneered the use of bevacizumab in AMD patients, comments:
"The CATT results, together with the totality of global experience, support the use of either bevacizumab (Avastin) or ranibizumab (Lucentis) for the treatment of neovascular AMD. An as needed regimen is an acceptable alternative to a monthly regimen, but strict compliance on the part of both the clinician and the patient is required. Health care providers and payers worldwide will now have to justify the cost of using ranibizumab (Lucentis). Regulators in certain countries will be forced to reconsider their policies that make it illegal to use drugs off-label, particularly when so many of their citizens cannot afford ranibizumab (Lucentis). The CATT data support the continued global use of intravitreal bevacizumab (Avastin) as an effective, low-cost alternative to ranibizumab (Lucentis)."
Read the full article from the New England Journal of Medicine
My take:
"The CATT study reaffirms that both drugs are very good. If a patient is doing well on one there is little reason to change to another. These results support an individualized approach to treatment. We look forward to the final result of this pivotal study in the next year."
Selina J. Lin, MD
11/05/2010:
Know Your Risk of Progression of Macular Degeneration with Macula Risk®
Dr. Selina Lin, a Board Certified, fellowship trained Retina and Macular Specialist introduces to our practice a DNA test called Macula Risk®. This test is used to identify genetic markers associated with macular degeneration progression. Learn your risk of macular degeneration.
Click here to learn more about Macula Risk®
09/20/2010:
Timothy Parker, O.D. Joins the Kaufman Eye Institute.
The Kaufman Eye Institute welcomes Timothy Parker, O.D. to our staff. Dr. Parker is a Florida Board Certified Optometrist.
Click here to learn more about Dr. Parker
10/13/2008:
Selina Lin, M.D. Joins the Kaufman Eye Institute.
The Kaufman Eye Institute welcomes Selina Lin, M.D. to our staff. Dr. Lin is a Board Certified, fellowship trained Retina and Macular Specialist.
Click here to learn more about Dr. Lin
07/15/2008:
Stuart J. Kaufman M.D. was interviewed in Ophthalmology Times in an article entitled “Eyelid cleanser can reduce bacterial colonization.” Published in Ophthalmology Times - June 23, 2008
In this article, Dr. Kaufman discusses his experience and recommendations with SteriLid the only bactericidal cleaner for the treatment of blepharitis.
Click here to download the article
06/23/2008:
Roger Gstalder, M.D. joins the Kaufman Eye Institute.
The Kaufman Eye Institute welcomes Roger Gstalder, M.D. to our staff. Dr. Gstalder is a Full Professor of Ophthalmology at the University of South Florida College of Medicine. He is Board Certified and specializes in Eyelid Surgery, Pediatrics, and Refractive Surgery.
Click here to learn more about Dr. Gstalder
04/2008:
The Kaufman Eye Institute was named a Crystalens® Center of Excellence by Bausch and Lomb.
The Kaufman Eye Institute is one of the first Crystalens® practices in Central Florida that has been awarded the high honor of being named a Crystalens® Center of Excellence. The Kaufman Eye Institute is one of about 100 practices in the United States noted for their experience and long term excellent outcomes.
01/15/2004:
Stuart J. Kaufman, M.D. implants the first Crystalens™ in Central Florida and the Tampa Bay Area.
Stuart J. Kaufman, M.D. is the first surgeon in Central Florida and the Tampa Bay Area to implant the Crystalens®. The Crystalens® is the only FDA approved accommodating lens implant which can correct distance, near, and intermediate vision. Most patients who have their cataracts removed and the Crystalens® implanted do not need any glasses after their cataract surgery. The revolutionary design element that makes the Crystalens® the state-of-the-art replacement lens are the hinges which are designed to allow the lens to move or accommodate and focus on objects near, far, and all distances in between seamlessly.
